rs11816667 (VWA2): AMD and VLDL Lipid Metabolism

Key takeaways

• rs11816667 is in the VWA2 (Von Willebrand factor A domain containing protein 2) gene, studied in research connecting blood lipid levels to age-related macular degeneration (AMD).
• Very small very low-density lipoprotein (VLDL) fractions in blood are likely causally linked to AMD development based on Mendelian randomization analysis.
• A UK Biobank study of 72,376 participants found 84 blood metabolites significantly associated with AMD, with lipoprotein subclasses accounting for 39% of those associations.
• Age is the dominant AMD risk factor; blood metabolites including lipoproteins contribute a smaller additional role.
• Evidence for this specific variant is preliminary and comes from a single study without independent replication.

What the research says A UK Biobank study analyzed 325 blood metabolites in 72,376 participants (1,353 with AMD, 71,023 controls) and identified 84 significantly associated with AMD after false discovery rate correction (FDR-adjusted P < 0.05), with lipoprotein subclasses comprising 39% of those associations. Genome-wide association studies (GWAS) were performed on all 325 metabolites in 98,316 European participants to identify genetic variants influencing metabolite levels. Using Mendelian randomization (an approach that treats genetic variants as natural experiments to test causal effects of a metabolite on a disease outcome), researchers identified 19 metabolites with likely causal roles in AMD, of which 6 were very small VLDL lipoprotein subclasses, leading the authors to conclude that depletion of circulating very small VLDLs is likely causal for AMD.

Reported associations

• Age-related macular degeneration: Very small VLDL lipoprotein subclasses in blood were identified as likely causally associated with AMD development through Mendelian randomization in a cohort of 72,376 UK Biobank participants (1,353 with AMD).
• Very small VLDL lipoprotein levels: Six very small VLDL-related metabolites were among 19 identified as likely causal for AMD; lipoprotein subclasses as a group comprised 39% of the 84 AMD-associated metabolites detected at FDR-adjusted P < 0.05.
• Large and extra-large HDL lipoprotein levels: Increased levels of large and extra-large high-density lipoprotein (HDL, a type of cholesterol carrier) subclasses were observed in AMD patients within the UK Biobank analysis.
• Amino acid and citrate levels: Decreased circulating amino acids and citrate were significantly associated with AMD in the same cohort.

Evidence quality The evidence comes from a single large UK Biobank study with 72,376 participants for metabolite-AMD association testing and 98,316 European participants for the metabolite GWAS. The use of Mendelian randomization strengthens causal inference compared to simple observational studies, and multiple testing was controlled using FDR correction. However, the provided study text focuses on metabolite-level findings and does not explicitly report a specific effect estimate for rs11816667 directly, limiting quantification of this individual variant's contribution. The authors note that age is the dominant predictor of AMD risk, with metabolites providing a much smaller supplementary contribution. No independent replication of the metabolite GWAS findings is described in the provided text, and the evidence for this specific variant should be considered preliminary.

Lifestyle considerations No lifestyle considerations on file for this variant.